NUVISAN GmbH
NUVISAN GmbH is a German full-service CRO/CDMO providing integrated drug discovery, preclinical, clinical, and GMP manufacturing services to pharmaceutical, biotechnology, and non-profit clients. Founded in 1979, it operates five European sites and has been a division of ALS Limited since April 2024.
- Company typePrivate
- Founded1979
- HeadquartersNeu-ulm, Germany
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What NUVISAN GmbH does
NUVISAN GmbH is a full-service contract research and manufacturing organization (CRO/CDMO) providing integrated drug discovery and development services from target identification through clinical development and GMP manufacturing. Founded in 1979 in Neu-Ulm, Germany, the company operates specialized centers of excellence in Berlin (drug discovery), Sophia Antipolis in France (formulation development and GMP manufacturing), and Neu-Ulm (bioanalysis and clinical trials clinic), with additional operational sites in Grafing and Waltrop, Germany. Service lines span five integrated modules: Discovery Services (omics and biomarkers, compound screening, pharmacology, chemistry, discovery DMPK), Preclinical Services (development DMPK, preclinical safety), Clinical Services (Phase 1 and 2, bioanalysis, biomarkers, clinical trial supply), CMC Services (drug substances, drug products, pharmaceutical analytical services, regulatory), and Digital Life Sciences (life science database, molecular modeling, cheminformatics and ML, bioinformatics). The company maintains therapeutic area specialization in oncology and dermatology, with modalities coverage including small molecules, biologics, and emerging formats such as antibody-drug conjugates.
NUVISAN operates under a professional services revenue model, with quote-based project pricing negotiated with each client on a contract basis. Customers include large and mid-sized pharmaceutical companies, biotechnology firms, venture capital portfolios, and non-profit organizations, with the Bill & Melinda Gates Foundation disclosed as a major non-profit partner via a US$25 million three-year grant for non-hormonal contraceptive research. The go-to-market motion is enterprise-focused, executed through a dedicated business development team using direct sales engagement complemented by industry conferences (SLAS Europe, CPHI, Eurotox), scientific publications, and digital channels. On April 1, 2024, NUVISAN was acquired by ALS Limited (ASX: ALQ), a public Australian diversified testing services group with operations in more than 350 locations across 55 countries, and now operates as a wholly-owned division of ALS while retaining its brand identity and leadership team.
The company is positioning for growth through three identifiable strategic vectors: AI-enabled drug discovery (participation in the €60+ million LIGAND-AI IHI consortium led by Pfizer and the Structural Genomics Consortium); women's health and global health verticals (Gates Foundation grant, Drug Discovery Innovation Challenge 2026 focused on women's health); and modality expansion via antibody-drug conjugate development (collaboration with Simris Biologics on Microcystin-based payloads). NUVISAN employs approximately 1,000 staff across five European sites, though the firmographic range indicates potential headcount of up to 5,000 within the broader ALS Group structure.
NUVISAN GmbH firmographics
Firmographics- Name
- NUVISAN GmbH
- Legal name
- Nuvisan GmbH
- Website
- https://nuvisan.com
- Company type
- Private
- Founded year
- 1979
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- NUVISAN GmbH is a German full-service CRO/CDMO providing integrated drug discovery, preclinical, clinical, and GMP manufacturing services to pharmaceutical, biotechnology, and non-profit clients. Founded in 1979, it operates five European sites and has been a division of ALS Limited since April 2024.
- Ownership category
- akta.pro rank
NUVISAN GmbH industry classification
Industry- Product category
- Pharmaceutical CRO/CDMO Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
Keywords
Where NUVISAN GmbH is headquartered
LocationHeadquarters
- HQ city
- Neu-ulm
- HQ country
- Germany
- HQ region
- Europe
Offices5 records
Markets served
NUVISAN GmbH business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Contract Research Services (CRO): Providing preclinical and clinical research services on a contract basis for pharmaceutical and biotech companies conducting drug discovery and development programs.
- Contract Development and Manufacturing (CDMO): GMP manufacturing and formulation development services for drug substances and drug products, including analytical services and regulatory support.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels7 records
NUVISAN GmbH product offering
Product offeringCore offering
Nuvisan is a full-service Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) delivering integrated drug discovery and development services across Discovery (omics & biomarkers, compound screening, pharmacology, chemistry, Discovery DMPK), Preclinical (Development DMPK, preclinical safety), Clinical (Phase 1 & 2, bioanalysis, biomarkers), CMC (drug substances, drug products, pharmaceutical analytical services, regulatory support), and Digital Life Sciences (molecular modelling, cheminformatics/ML, bioinformatics & omics analysis). Services can be procured individually or as integrated end-to-end programs with therapeutic-area expertise in dermatology and oncology, executed through GLP/GMP-certified centers of excellence in Berlin, Sophia Antipolis, and Neu-Ulm.
Product overview
Nuvisan GmbH is a full-service Contract Research Organization (CRO) and Development/Manufacturing Organization (CDMO) offering end-to-end drug discovery and development solutions. The company operates as a unified platform with interconnected service modules spanning Discovery Services (Omics & Biomarkers, Biosciences, Compound Screening, Pharmacology, Chemistry, Discovery DMPK), Preclinical Services (Development DMPK, Preclinical Safety), Clinical Services (Phase 1 & 2, Bioanalysis, Biomarkers), CMC Services (Drug Substances, Drug Products, Pharmaceutical Analytical Services, Regulatory), Digital Life Sciences (Life Science Database, Digital Science Technologies, Molecular Modelling, Cheminformatics & ML, Bioinformatics & Omics Data Analysis), and Integrated Solutions (Dermatology, Oncology, Modalities, Research Phases). The company has unique centers of excellence in Berlin (drug discovery), Sophia Antipolis (formulation and GMP manufacturing), and Neu-Ulm (bioanalysis). Services are designed to be used independently or as an integrated package, with recent AI-driven initiatives including participation in the LIGAND-AI project for AI-powered drug discovery.
Differentiator
Problem solved
Functional benefit
Products and services
- Discovery Services Comprehensive drug discovery services covering omics and biomarkers, biosciences, compound screening using 384-well plate technology, pharmacology, chemistry, and Discovery DMPK. Designed to help pharmaceutical and biotechnology clients achieve key decision milestones through deep scientific insights across multiple therapeutic areas.
- Preclinical Services Preclinical development services including Development DMPK and preclinical safety studies to successfully develop and de-risk preclinical candidates for smooth transition to clinical phases. Serves pharmaceutical and biotech clients preparing assets for first-in-human studies.
- Clinical Services Clinical trial services for Phase 1 and Phase 2 studies, including bioanalysis, biomarkers, and clinical trial supply services to fully assess drugs faster. Supports early-stage clinical development for pharmaceutical and biotech sponsors.
- CMC Services Chemistry, Manufacturing, and Controls services covering drug substances, drug products, pharmaceutical analytical services, clinical trial supply, and regulatory support to advance molecules into drug products. Includes GMP manufacturing capability based at the Sophia Antipolis (Biot) center of excellence in France.
- Digital Life Sciences Digital life sciences services including life science database, digital science technologies, molecular modelling, cheminformatics & machine learning, and bioinformatics & omics data analysis. Empowers drug discovery with integrated data services and AI for pharmaceutical and biotechnology clients.
- Integrated Solutions End-to-end integrated drug discovery and development solutions combining Discovery, Preclinical, Clinical, CMC, and Digital services with tailored programs across therapeutic areas including dermatology and oncology. Sold as a packaged offering where clients can outsource the full development value chain to a single scientific partner.
Quantifiable outcome
- Received US$25 million grant from Gates Foundation for non-hormonal contraceptive research
- +1 more outcomes
Companies that use NUVISAN GmbH
Customer profileNamed customers4 records
Segments1 record
Ideal customer profiles4 records
NUVISAN GmbH technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability10 records
Feature5 records
NUVISAN GmbH partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship and minor.
- LIGAND-AI (IHI Project)flagshipInnovative Health Initiative project led by Pfizer and Structural Genomics Consortium (SGC) with 18 partners across 9 countries and budget exceeding €60 million. Aims to generate large, open, high-quality datasets of protein-ligand interactions to train AI models. Nuvisan contributes to setting new benchmarks for open and standardized data generation in drug discovery.
- Simris Group AB / Simris Biologics GmbHminorCollaboration on preclinical ADC (Antibody-Drug Conjugate) study. Successful generation and efficacy testing of proprietary Microcystin-based payloads, with ADC variant SIMRIS-121 demonstrating full cytotoxicity against cancer cells.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
NUVISAN GmbH competitors and assessment
Company assessmentBroad incumbents
- Lonza Group: Swiss-based global CDMO with biologics and small molecule manufacturing capabilities. Comparable in CDMO services but at significantly larger scale across multiple modalities.
- Charles River Laboratories: Large US-headquartered CRO/CDMO providing discovery, safety assessment, and manufacturing services. Overlaps with Nuvisan across preclinical safety, bioanalysis, and CMC but at significantly greater scale and global reach.
- IQVIA: World's largest CRO with comprehensive clinical, real-world evidence, and technology-enabled services. Competes with Nuvisan's clinical Phase 1 & 2 services and broader drug development offerings.
- ICON plc: Global CRO focused on clinical research and laboratory services with biopharmaceutical clients worldwide. Comparable clinical services footprint to Nuvisan's Phase 1 & 2 and bioanalysis offerings.
- Labcorp Drug Development (formerly Covance): Major CRO offering early development, central labs, clinical trials, and commercialization services. Overlaps with Nuvisan in discovery, preclinical, clinical, and bioanalysis services at much larger scale.
- Catalent (Novo Holdings): Large CDMO specializing in drug substance, drug product, and clinical supply services. Directly comparable to Nuvisan's CMC offering including GMP manufacturing in Sophia Antipolis.
- Eurofins Scientific: Global testing services group with extensive bioanalytical, central lab, and pharmaceutical services. Overlaps with Nuvisan's bioanalysis and analytical services and shares some integration logic with ALS Limited (Nuvisan's parent).
Direct peers
- Evotec SE: Germany-headquartered contract research organization offering end-to-end drug discovery and development services spanning target identification through preclinical and clinical support. Highly comparable to Nuvisan in integrated CRO model, therapeutic area focus, and European footprint.
- WuXi AppTec: China-headquartered CRO/CDMO offering integrated discovery, preclinical, clinical, and manufacturing services. Comparable integrated end-to-end model though with broader geographic footprint and larger scale.
Others
- Sartorius AG: German bioprocessing supplier providing equipment and services for pharmaceutical manufacturing. Adjacent rather than direct competitor but shares German mid-cap life sciences positioning and biopharma customer base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
NUVISAN GmbH social profiles
Digital presenceNUVISAN GmbH financial estimates
Financial estimateRevenue estimate
Valuation estimate
NUVISAN GmbH leadership team
Management profileNumber of profiles
Profiles8 records
NUVISAN GmbH funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NUVISAN GmbH M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NUVISAN GmbH
What does NUVISAN GmbH do?
Nuvisan is a full-service Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) delivering integrated drug discovery and development services across Discovery (omics & biomarkers, compound screening, pharmacology, chemistry, Discovery DMPK), Preclinical (Development DMPK, preclinical safety), Clinical (Phase 1 & 2, bioanalysis, biomarkers), CMC (drug substances, drug products, pharmaceutical analytical services, regulatory support), and Digital Life Sciences (molecular modelling, cheminformatics/ML, bioinformatics & omics analysis). Services can be procured individually or as integrated end-to-end programs with therapeutic-area expertise in dermatology and oncology, executed through GLP/GMP-certified centers of excellence in Berlin, Sophia Antipolis, and Neu-Ulm.
Is NUVISAN GmbH a public or private company?
NUVISAN GmbH is a private company. It is classified as corporate owned and is currently operating.
When was NUVISAN GmbH founded?
NUVISAN GmbH was founded in 1979. It employs 1,001 to 5,000 people.
Where is NUVISAN GmbH based?
NUVISAN GmbH is headquartered in Neu-ulm, Germany, in the Europe region.
How does NUVISAN GmbH make money?
Two revenue lines are on record. Contract Research Services (CRO) is the primary driver. The others are contract Development and Manufacturing (CDMO).
Who are NUVISAN GmbH's main competitors?
Broad incumbents on record are Lonza Group, Charles River Laboratories, IQVIA, ICON plc, Labcorp Drug Development (formerly Covance), Catalent (Novo Holdings) and Eurofins Scientific. Direct peers are Evotec SE and WuXi AppTec. Sartorius AG is listed as an others.
Does NUVISAN GmbH have an API?
No public API is recorded for NUVISAN GmbH.
What industry is NUVISAN GmbH in?
NUVISAN GmbH's product category is Pharmaceutical CRO/CDMO Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 541714 and its SIC code is 8731.